Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome

 

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribute to the final pathway of inflammation that leads to CVD. MetS has gained significant importance recently due to the exponential increase in obesity worldwide. Early diagnosis is important in order to employ lifestyle and risk factor modification. Here, we review the epidemiology and pathogenesis of MetS, the role of inflammation in MetS, and summarize existing natural therapies for MetS.

  • Pathways and Mechanisms
  • Linkage and heredity associations
  • Insulin resistance and Glucose intolerance
  • Obesity and increased waist circumference
  • Dyslipidaemia and Hypertension
  • Etiology of endocrine disorders
  • Complications of diabetes mellitus
  • Associated autoimmune conditions

Related Conference of Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome

March 25-26, 2024

5th Annual Conference on Diabetes

London, UK
July 11-12, 2024

7th Annual Meeting on Diabetes and Endocrinology

Paris, France
September 09-10, 2024

4th European Endocrinology and Diabetes Congress

Paris, France
November 22-23, 2024

20th World Congress on Endocrinology & Diabetes

Amsterdam, Netherlands

Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in